Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ravulizumab in Pediatric Participants With Primary Immunoglobulin A Nephropathy (IgAN)
NCT07024563Phase 3Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of ravulizumab in immunoglobulin A nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Jun 2025; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07024563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07024563.